The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.

Truist analyst Joon Lee raised the firm’s price target on Axsome Therapeutics (AXSM) to $190 from $180 and keeps a Buy rating on the shares.

Baird analyst Joel Beatty raised the firm’s price target on Axsome Therapeutics (AXSM) to $132 from $116 and keeps an Outperform rating on the ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS ...

Truist Securities adjusted their financial outlook for Axsome Therapeutics (NASDAQ:AXSM), increasing the price target to $190 from the previous $180 while maintaining a Buy rating on the company's ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company has been gaining significant ...

Clinical trials demonstrated that a single dose of Symbravo provides rapid migraine relief, sustains efficacy for up to 48 ...

Royal Bank of Canada reaffirmed their outperform rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report published on Wednesday morning,Benzinga reports. They currently have a ...

Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.